What is Tango Therapeutics's gross unrealized gains?

Tango Therapeutics (TNGX) reported gross unrealized gains of $19K in Q1 2026.

How has Tango Therapeutics's gross unrealized gains changed year-over-year?

Tango Therapeutics's gross unrealized gains decreased by 91.4% year-over-year, from $221K to $19K.

What is the long-term trend for Tango Therapeutics's gross unrealized gains?

Over 5 years (2020 to 2025), Tango Therapeutics's gross unrealized gains has grown at a 67.5% compound annual growth rate (CAGR), from $17K to $224K.

Tango Therapeutics TNGX Gross Unrealized Gains

Gross Unrealized Gains at other companies

AmgenAMGN

——

Gilead SciencesGILD

——

ExelixisEXEL

——

Guardant HealthGH

——

Jazz PharmaceuticalsJAZZ

——

Other financials

Income statement

See full

Revenue--100%

Operating income-$48.8M-14.7%

Net income-$45.5M-14.1%

EPS (diluted)-$0.32+11.1%

Balance sheet

See full

Cash & equivalents$160.0M+162%

Total debt$32.8M-11.3%

Total equity$391.5M+135%

Total assets$435.8M+58.9%

Cash flow

See full

Operating cash flow-$44.4M-6.4%

CapEx-$2.0K-104%

Free cash flow-$44.4M-6.3%

Valuation

See full

Market cap$4.55B+1,915%

Profitability

See full

Operating margin-206.2%-61.0pp

Net margin-188.2%-55.4pp

FCF margin-250.1%-49.4pp

Returns & leverage

See full

Return on equity-38.4%-10.5pp

Debt / equity0.1×-0.1×

Current ratio27.4×+21.1×

Where this comes from

Reported directly by Tango Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax.

The official record: Tango Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tango Therapeutics's gross unrealized gains.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Tango Therapeutics's gross unrealized gains?: Tango Therapeutics (TNGX) reported gross unrealized gains of $19K in Q1 2026.
How has Tango Therapeutics's gross unrealized gains changed year-over-year?: Tango Therapeutics's gross unrealized gains decreased by 91.4% year-over-year, from $221K to $19K.
What is the long-term trend for Tango Therapeutics's gross unrealized gains?: Over 5 years (2020 to 2025), Tango Therapeutics's gross unrealized gains has grown at a 67.5% compound annual growth rate (CAGR), from $17K to $224K.